Bigfoot Biomedical said today that it inked a non-exclusive deal with Eli Lilly (NYSE:LLY) to integrate Eli Lilly’s insulin products into Bigfoot’s investigational insulin delivery devices. The California-based company expects to launch its first two insulin delivery systems – Bigfoot Inject and Bigfoot Loop – in 2020, contingent upon finishing a pivotal trial and landing regulatory approvals. Get […]
Featured
Dexcom Q4 prelims top consensus | Wall Street Beat
Dexcom (NSDQ:DXCM) topped estimates on Wall Street today with preliminary results for its fourth-quarter financial results. The San Diego, Calif.-based company said it expects to report $331 million in sales for the quarter ended Dec. 31 – up at least 50% from the same period last year. Get the full story at our sister site, Drug […]
Abiomed jumps on fiscal Q3 prelims, raised outlook | Wall Street Beat
Abiomed (NSDQ:ABMD) shares got a jump today from its preliminary fiscal third-quarter numbers and an improved outlook for the rest of its fiscal year. The Danvers, Mass.-based heart pump maker said it expects to post fiscal Q3 sales of roughly $200.6 million, representing a 30.3% increase over its fiscal Q3 top line. Abiomed also raised […]
JC Medical touts first U.S. treatment with transfemoral TAVR system
JC Medical said today that the company’s first U.S.-based patient was treated with its transfemoral transcatheter aortic valve implant system, J-Valve TF. The FDA approved the use of J-Valve for people with aortic regurgitation through its “compassionate use” pathway. JC Medical also noted that it’s gearing up for a clinical trial of the investigational device in […]
Monteris Medical had a serious recall: Here’s what their CEO did
Soon after Marty Emerson took over as CEO of Monteris Medical, he and other company officials realized that the company’s robot-assisted brain surgery device had a serious overheating problem. Here’s how he led the company through the crisis. Marty Emerson became CEO of Monteris Medical (Plymouth, Minn.) in July 2016. Within a month, the first […]
Obalon plunges on trimmed 2018 sales guidance
Obalon Therapeutics (NSDQ:OBLN) shares took a big hit yesterday and continued their slide today after the weight loss balloon maker said it expected to hit the low end of its 2018 sales guidance. Carlsbad, Calif.-based Obalon said last year’s revenues are headed toward the low end of its prior outlook for $9.0 million to $9.9 […]
Minerva Surgical raises $9m for endometrial ablation tech
Minerva Surgical has raised $9.2 million from 17 investors as part of a $10 million offering, according to a document filed with the SEC this week. The Redwood City, CA.-based company makes the Minerva endometrial ablation system – a treatment designed to help women manage heavy menstrual bleeding. Heaving bleeding, which occurs in women between […]
Endologix recalls Nellix stent graft, bans off-label use
Endologix (NSDQ:ELGX) said today that it’s halting the unrestricted sale of its Nellix stent graft for treating abdominal aortic aneurysms and limiting its use to pre-screened patients under a clinical protocol. “We monitor the performance of the Nellix system through clinical trials, our complaint monitoring system, physician interaction and available publications,” CMO Dr. Matt Thompson said […]
AngioDynamics beats The Street with Q2 results
Shares in AngioDynamics (NSDQ:ANGO) rose today after the medical device maker topped expectations on Wall Street with its second quarter financial results. The Latham, N.Y.-based company posted profits of $2.1 million, or 6¢ per share, on sales of $91.5 million for the 3 months ended Nov. 30, for sales growth of 5.5% compared with the same […]
Senseonics touts first U.S. trial implant of 180-day CGM
Senseonics (NYSE:SENS) said yesterday that its Eversense XL 180-day continuous glucose sensor was implanted into the first participant of a trial designed to support a pre-market application to the FDA. The company’s 180-patient Promise trial is slated to study the safety and efficacy of the Eversense device in people with diabetes over 180 days. Get the […]
Verily eyes new deals with $1B to back them
Alphabet‘s (NSDQ:GOOGL) life sciences group, Verily, said yesterday that it raised $1 billion from a group of investors, including private equity firm Silver Lake and the Ontario Teachers’ Pension Plan. The company plans to use its newly-raised funds to support strategic partnerships and potential acquisitions. In a statement, Verily announced that Alphabet’s chief financial officer, […]
